

Application No. : 10/727,155
Filed : December 2, 2003

AMENDMENTS TO THE CLAIMS

1.-43. (Cancelled)

44. (Withdrawn) A method for assaying the level of tumor necrosis factor alpha (TNF α) in a patient sample, comprising contacting an anti-TNF α antibody of Claim 1 or Claim 23 with a biological sample from a patient, and detecting the level of binding between said antibody and TNF α in said sample.

45. (Withdrawn) The method according to Claim 44 wherein the biological sample is blood.

46. (Cancelled)

47. (Withdrawn) A method of effectively treating an animal suffering from a neoplastic disease, comprising:

selecting an animal in need of treatment for a neoplastic disease; and

administering to said animal a therapeutically effective dose of a fully human monoclonal antibody of Claim 1 or Claim 23 that specifically binds to tumor necrosis factor alpha (TNF α).

48. (Withdrawn) The method of claim 47, wherein said neoplastic disease is selected from the group consisting of: breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, stomach cancer, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and prostate cancer.

49. (Withdrawn) A method of effectively treating an immuno-mediated inflammatory disease, comprising:

selecting an animal in need of treatment for an inflammatory condition; and

administering to said animal a therapeutically effective dose of a fully human monoclonal antibody of Claim 1 or Claim 23, wherein said antibody specifically binds to tumor necrosis factor alpha (TNF α).

50. (Withdrawn) The method of claim 49, wherein said immuno-mediated inflammatory disease is selected from the group consisting of: rheumatoid arthritis, glomerulonephritis, atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's disease, graft-host reactions, septic shock, cachexia, anorexia, ankylosing spondylitis and multiple sclerosis.

Application No. : 10/727,155
Filed : December 2, 2003

51. (Withdrawn) A method of inhibiting tumor necrosis factor alpha (TNF α) induced apoptosis in an animal, comprising:

selecting an animal in need of treatment for TNF α induced apoptosis; and

administering to said animal a therapeutically effective dose of a fully human monoclonal antibody of Claim 1 or Claim 23, wherein said antibody specifically binds to TNF α .

52.-56. (Cancelled)

57. (New) A fully human monoclonal antibody, or binding fragment thereof, that binds to Tumor Necrosis Factor- α , wherein the antibody, or binding fragment thereof, comprises a light chain polypeptide having the amino acid sequence of SEQ ID NO. 72.

58. (New) The antibody, or binding fragment thereof, of Claim 57, wherein the antibody further comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 74.

59. (New) The antibody, or binding fragment thereof, of Claim 58, wherein said antibody, or binding fragment thereof, is a complete antibody.

60. (New) The antibody, or binding fragment thereof, of Claim 59, wherein the antibody is monoclonal antibody 299v2.

61. (New) The antibody, or binding fragment thereof, of Claim 57, wherein the antibody is in association with a pharmaceutically acceptable carrier.

62. (New) The antibody, or binding fragment thereof, of Claim 57, wherein said antibody, or binding fragment thereof, is a binding fragment of an antibody.

63. (New) The antibody, or binding fragment thereof, of Claim 57, wherein said antibody is conjugated to a therapeutic agent.

64. (New) The antibody, or binding fragment thereof, of Claim 63, wherein the therapeutic agent is a toxin.

65. (New) The antibody, or binding fragment thereof, of Claim 63, wherein the therapeutic agent is a radioisotope.

66. (New) The antibody, or binding fragment thereof, of Claim 57, wherein the antibody further comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 70.

Application No. : 10/727,155
Filed : December 2, 2003

67. (New) The antibody, or binding fragment thereof, of Claim 66, wherein said antibody, or binding fragment thereof, is a complete antibody.

68. (New) The antibody, or binding fragment thereof, of Claim 67, wherein the antibody is monoclonal antibody 299v1.

69. (New) The antibody, or binding fragment thereof, of Claim 66, wherein the antibody is in association with a pharmaceutically acceptable carrier.

70. (New) A fully human monoclonal antibody, or binding fragment thereof, that binds to Tumor Necrosis Factor- α , wherein the antibody, or binding fragment thereof, comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO. 74.

71. (New) A fully human monoclonal antibody, or binding fragment thereof, that binds to Tumor Necrosis Factor- α , wherein the antibody, or binding fragment thereof, comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO. 70.

72. (New) A fully human monoclonal antibody, or binding fragment thereof, that binds to Tumor Necrosis Factor- α , wherein the antibody, or binding fragment thereof, comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO. 50.

73. (New) The antibody, or binding fragment thereof, of Claim 72, wherein the antibody further comprises a light chain polypeptide having the amino acid sequence of SEQ ID NO. 52.

74. (New) The antibody, or binding fragment thereof, of Claim 73, wherein said antibody, or binding fragment thereof, is a complete antibody.

75. (New) The antibody, or binding fragment thereof, of Claim 74, wherein the antibody is monoclonal antibody 263.

76. (New) The antibody, or binding fragment thereof, of Claim 72, wherein the antibody is in association with a pharmaceutically acceptable carrier.

77. (New) The antibody, or binding fragment thereof, of Claim 72, wherein said antibody, or binding fragment thereof, is a binding fragment of an antibody.

78. (New) The antibody, or binding fragment thereof, of Claim 72, wherein said antibody is conjugated to a therapeutic agent.

79. (New) The antibody, or binding fragment thereof, of Claim 78, wherein the therapeutic agent is a toxin.

Application No. : 10/727,155
Filed : December 2, 2003

80. (New) The antibody, or binding fragment thereof, of Claim 78, wherein the therapeutic agent is a radioisotope.

81. (New) A fully human monoclonal antibody, or binding fragment thereof, that binds to Tumor Necrosis Factor- α , wherein the antibody, or binding fragment thereof, comprises a light chain polypeptide having the amino acid sequence of SEQ ID NO. 52.

82. (New) A fully human monoclonal antibody, or binding fragment thereof, that binds to Tumor Necrosis Factor- α , wherein the antibody, or binding fragment thereof, comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO. 54.

83. (New) The antibody, or binding fragment thereof, of Claim 82, wherein the antibody further comprises a light chain amino acid sequence of SEQ ID NO. 56.

84. (New) The antibody, or binding fragment thereof, of Claim 83, wherein said antibody, or binding fragment thereof, is a complete antibody.

85. (New) The antibody, or binding fragment thereof, of Claim 84, wherein the antibody is monoclonal antibody 269.

86. (New) The antibody, or binding fragment thereof, of Claim 82, wherein the antibody is in association with a pharmaceutically acceptable carrier.

87. (New) The antibody, or binding fragment thereof, of Claim 82, wherein said antibody, or binding fragment thereof, is a binding fragment of an antibody.

88. (New) The antibody, or binding fragment thereof, of Claim 82, wherein said antibody is conjugated to a therapeutic agent.

89. (New) The antibody, or binding fragment thereof, of Claim 88, wherein the therapeutic agent is a toxin.

90. (New) The antibody, or binding fragment thereof, of Claim 88, wherein the therapeutic agent is a radioisotope.

91. (New) A fully human monoclonal antibody, or binding fragment thereof, that binds to Tumor Necrosis Factor- α , wherein the antibody, or binding fragment thereof, comprises a light chain polypeptide having the amino acid sequence of SEQ ID NO. 56.

92. (New) A fully human monoclonal antibody, or binding fragment thereof, that binds to Tumor Necrosis Factor- α , wherein the antibody, or binding fragment thereof, comprises a light chain polypeptide having the amino acid sequence of SEQ ID NO. 48.

Application No. : 10/727,155
Filed : December 2, 2003

93. (New) The antibody, or binding fragment thereof, of Claim 92, wherein said antibody, or binding fragment thereof, is a complete antibody.

94. (New) The antibody, or binding fragment thereof, of Claim 92, wherein the antibody is in association with a pharmaceutically acceptable carrier.

95. (New) The antibody, or binding fragment thereof, of Claim 92, wherein said antibody, or binding fragment thereof, is a binding fragment of an antibody.

96. (New) The antibody, or binding fragment thereof, of Claim 92, wherein said antibody is conjugated to a therapeutic agent.

97. (New) The antibody, or binding fragment thereof, of Claim 96, wherein the therapeutic agent is a toxin.

98. (New) The antibody, or binding fragment thereof, of Claim 96, wherein the therapeutic agent is a radioisotope.

99. (New) A fully human monoclonal antibody that binds to Tumor Necrosis Factor- α , wherein the monoclonal antibody is monoclonal antibody 299v2.

100. (New) The antibody of Claim 99, wherein the antibody comprises a light chain polypeptide having the amino acid sequence of SEQ ID NO. 72.

101. (New) The antibody of Claim 99, wherein the antibody comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO. 74.

102. (New) The antibody of Claim 99, wherein the antibody is in association with a pharmaceutically acceptable carrier.

103. (New) A fully human monoclonal antibody that binds to Tumor Necrosis Factor- α , wherein the monoclonal antibody is monoclonal antibody 299v1.

104. (New) The antibody of Claim 103, wherein the antibody comprises a light chain polypeptide having the amino acid sequence of SEQ ID NO. 72.

105. (New) The antibody of Claim 103, wherein the antibody comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO. 70.

106. (New) The antibody of Claim 103, wherein the antibody is in association with a pharmaceutically acceptable carrier.